• No results found

A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy

N/A
N/A
Info
Downloaden
Protected

Academic year: 2021

Share "A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy"

Copied!
12
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Download het nu ( 12 pagina )

Hele tekst

(1)

6/14/2019 A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Elsev…

https://reader.elsevier.com/reader/sd/pii/S0960896617302006?token=27F141DC296BAC3DED2F4A1ABCB6FBF473A540F5D489A09B2FE9C… 1/12

(2)

6/14/2019 A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Elsev…

https://reader.elsevier.com/reader/sd/pii/S0960896617302006?token=27F141DC296BAC3DED2F4A1ABCB6FBF473A540F5D489A09B2FE9C… 2/12

(3)

6/14/2019 A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Elsev…

https://reader.elsevier.com/reader/sd/pii/S0960896617302006?token=27F141DC296BAC3DED2F4A1ABCB6FBF473A540F5D489A09B2FE9C… 3/12

(4)

6/14/2019 A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Elsev…

https://reader.elsevier.com/reader/sd/pii/S0960896617302006?token=27F141DC296BAC3DED2F4A1ABCB6FBF473A540F5D489A09B2FE9C… 4/12

(5)

6/14/2019 A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Elsev…

https://reader.elsevier.com/reader/sd/pii/S0960896617302006?token=27F141DC296BAC3DED2F4A1ABCB6FBF473A540F5D489A09B2FE9C… 5/12

(6)

6/14/2019 A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Elsev…

https://reader.elsevier.com/reader/sd/pii/S0960896617302006?token=27F141DC296BAC3DED2F4A1ABCB6FBF473A540F5D489A09B2FE9C… 6/12

(7)

6/14/2019 A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Elsev…

https://reader.elsevier.com/reader/sd/pii/S0960896617302006?token=27F141DC296BAC3DED2F4A1ABCB6FBF473A540F5D489A09B2FE9C… 7/12

(8)

6/14/2019 A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Elsev…

https://reader.elsevier.com/reader/sd/pii/S0960896617302006?token=27F141DC296BAC3DED2F4A1ABCB6FBF473A540F5D489A09B2FE9C… 8/12

(9)

6/14/2019 A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Elsev…

https://reader.elsevier.com/reader/sd/pii/S0960896617302006?token=27F141DC296BAC3DED2F4A1ABCB6FBF473A540F5D489A09B2FE9C… 9/12

(10)

6/14/2019 A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Elsev…

https://reader.elsevier.com/reader/sd/pii/S0960896617302006?token=27F141DC296BAC3DED2F4A1ABCB6FBF473A540F5D489A09B2FE9… 10/12

(11)

6/14/2019 A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Elsev…

https://reader.elsevier.com/reader/sd/pii/S0960896617302006?token=27F141DC296BAC3DED2F4A1ABCB6FBF473A540F5D489A09B2FE9C… 11/12

(12)

6/14/2019 A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy | Elsev…

https://reader.elsevier.com/reader/sd/pii/S0960896617302006?token=27F141DC296BAC3DED2F4A1ABCB6FBF473A540F5D489A09B2FE9… 12/12

Referenties

Download het nu ( PDF - 12 pagina - 6.97 MB )

GERELATEERDE DOCUMENTEN

Refinement of antisense oligonucleotide mediated exon skipping as therapy for Duchenne muscular dystrophy

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden Downloaded.

Refinement of antisense oligonucleotide mediated exon skipping as therapy for Duchenne muscular dystrophy Heemskerk, J.A.

The studies described in this thesis have been performed at the Leiden University Medical Center, department of human genetics. This work was financially supported by the Dutch

Refinement of antisense oligonucleotide mediated exon skipping as therapy for Duchenne muscular dystrophy Heemskerk, J.A.

Using this ‘B-peptide’ to deliver a PMO targeting exon 23 in mdx mice showed high levels of exon skipping and dystrophin protein, even in heart, in which skipping levels are

Refinement of antisense oligonucleotide mediated exon skipping as therapy for Duchenne muscular dystrophy Heemskerk, J.A.

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded

Refinement of antisense oligonucleotide mediated exon skipping as therapy for Duchenne muscular dystrophy Heemskerk, J.A.

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden. Downloaded

A Drosophila model for Duchenne muscular dystrophy Plas, M.C. van der

The absence of the Dystrophin DLP2 and Dp186 isoforms or reduction of their expression levels results in an increased amount of evoked neurotransmitter release, which

A Drosophila model for Duchenne muscular dystrophy Plas, M.C. van der

De spier degeneratie in DMD patiënten wordt wellicht niet primair veroorzaakt door de afwezigheid van Dystrofine, maar door de afwezigheid van andere DGC eiwitten,

Research on Duchenne muscular dystrophy

[r]